Quick Takeaways
- Propel Bio Management, LLC filed SCHEDULE 13G/A for Applied Therapeutics, Inc. Common Stock (APLT).
- Disclosed ownership: 4.2%.
- Date of event: 29 Dec 2025.
Propel Bio Management, LLC - 29 Dec 2025 SCHEDULE 13G/A Report for Applied Therapeutics, Inc. Common Stock (APLT)
- Filing Manager
- Propel Bio Management, LLC
- Reporting Manager
- Propel Bio Management, LLC
- Symbol
- APLT
- Shares outstanding
- 143,223,667 shares
- Disclosed Ownership
- 6,015,394 shares
- Ownership
- 4.2%
- Form type
- SCHEDULE 13G/A
- Filing time
- 31 Dec 2025, 12:29:50 UTC
- Date of event
- 29 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Propel Bio Management, LLC disclosed 4.2% ownership in Applied Therapeutics, Inc. Common Stock (APLT) on 29 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 31 Dec 2025, 12:29.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (5)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Propel Bio Management, LLC | 4.2% | 6,015,394 | 6,015,394 | 0 | Leen Kawas | Managing Member | |
| Leen Kawas | 4.2% | 6,015,394 | 6,015,394 | 0 | Leen Kawas | Individual | |
| Richard Kayne and Suzanne Kayne Living Trust dtd 01/14/1999 | 0% | 0 | 0 | 0 | Richard Kayne | Trustee | |
| Richard Kayne | 4.2% | 6,015,394 | 6,015,394 | 0 | Richard Kayne | Individual | |
| Propel Bio Partners LLC | 4.2% | 6,015,394 | 6,015,394 | 0 | Leen Kawas | Managing Member |